Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mead Johnson Eyes China’s One-Child Policy, Hong Kong Formula Rule

This article was originally published in PharmAsia News

Executive Summary

The one-child policy in much of China stifles Mead Johnson’s annual formula volume growth there, says incoming CEO Kasper Jakobsen. Formula sales there could be slowed with Hong Kong limiting the amount that consumers can take out of the territory.

You may also be interested in...



People In Brief

Jakobsen next in line as Mead Johnson CEO; Blake takes over Bayer U.S. from Babe; Himmel ends brief tenure as ChromaDex CEO; Capitol Hill veteran O’Donnell joins NACDS; Merz makes Hartman derma VP; USANA strengthens scientist roster; more People In Brief.

Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer

Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025.  It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.

‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation

CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC084195

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel